TheraRadar
← Back
Data updated: Mar 29, 2026

MALLINCKRODT IRELAND

RespiratoryCardiovascularGastroenterology
Specialty

MALLINCKRODT IRELAND is a specialty pharmaceutical company focused on Respiratory, Cardiovascular, Gastroenterology. Key products include TERLIVAZ.

1952
Since
4
Drugs
-
Trials
0
Approved (2yr)

Key Drugs

TERLIVAZ
terlipressin acetate
Vasopressin V1 receptor 1 indications · 2022

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

No recent activity
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Respiratory 33%
1 drugs Phase 1: 1
Cardiovascular 29%
1 drugs
Gastroenterology 29%
0 drugs Phase 3: 1 Phase 2: 1
Immunology 10%
0 drugs Phase 1: 2

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Novartis big-pharma
Cardiovascular, Immunology, Respiratory
LEGACY PHARMA big-pharma
Respiratory, Gastroenterology, Immunology, Cardiovascular
BAUSCH specialty
Immunology, Cardiovascular, Gastroenterology
AstraZeneca big-pharma
Respiratory, Cardiovascular, Immunology
COREPHARMA other
Cardiovascular, Respiratory, Immunology, Gastroenterology